Trial Profile
Phase I/II trial of the tolerability and preliminary efficacy of APC 100 for the treatment of hormone-refractory (castrate-resistant) prostate cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs APC 100 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Adamis Pharmaceuticals Corporation
- 29 Feb 2016 Results (n=20) published in the Investigational New Drugs
- 15 Jul 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2017 as per ClinicalTrials.gov record.
- 15 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.